AMGLIDIA 0.6 mg/ml, oral suspension bottle, 30 ml, CIP 3400930149911
Active ingredients: Glyburide
Commercialized according to BDPMDispensing in France: Prescription only
Oral suspensionbottle, 30 ml, CIP 3400930149911orale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- AMGLIDIA 0,6 mg/mL, suspension buvable
- Pharmaceutical form
- suspension buvable
- Route of administration
- orale
- Presentation description
- 1 flacon(s) en verre brun avec fermeture de sécurité enfant de 30 ml avec adaptateur pour seringue avec seringue graduée pour administration orale de 1 ml
- Marketing authorisation holder
- AMMTEK
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 5 Jun 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Initial prescription by a specialist
- Renewal by a specialist only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61791198CIP73014991CIP133400930149911Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| GLIBENCLAMIDEsuspension | 0,6 mg · 1 mL de suspension | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.